TipRanks
AstraZeneca PLC (SE:AZN)
:AZN
Sweden Market
AZN
AstraZeneca
RESEARCH TOOLSreports

AstraZeneca (AZN) Stock Forecast & Price Target

8 Followers
See the Price Targets and Ratings of:

AZN Analyst Ratings

Strong Buy
16Ratings
Strong Buy
14 Buy
2 Hold
0 Sell
Based on 16 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

kr2,079.96
▲(33.42% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is kr2,079.96 with a high forecast of kr2,623.81 and a low forecast of kr1,550.61. The average price target represents a 33.42% change from the last price of kr1,559.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1526":"kr1,526","2075":"kr2,075","2624":"kr2,624","1800.5":"kr1,800.5","2349.5":"kr2,349.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2623.808088,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr2.62K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2079.95758677,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr2.08K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1550.61361845,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr1.55K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1526,1800.5,2075,2349.5,2624],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1599,1677.8313913846155,1756.6627827692307,1835.4941741538462,1914.3255655384617,1993.156956923077,2071.9883483076924,2150.819739692308,2229.6511310769233,2308.482522461539,2387.313913846154,2466.1453052307693,2544.9766966153848,{"y":2623.808088,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1599,1635.996737443846,1672.9934748876924,1709.9902123315385,1746.9869497753846,1783.983687219231,1820.980424663077,1857.977162106923,1894.9738995507691,1931.9706369946155,1968.9673744384615,2005.9641118823079,2042.960849326154,{"y":2079.95758677,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1599,1595.27797065,1591.5559413,1587.8339119500001,1584.1118826,1580.38985325,1576.6678239,1572.94579455,1569.2237652000001,1565.5017358500002,1561.7797065,1558.05767715,1554.3356478,{"y":1550.61361845,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1541.527,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1527.764,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1697.843,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1674.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1687.028,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1859.003,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1859.003,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1721.924,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1667.292,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1780.53,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1616.632,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1555.5,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 72,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1599,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Targetkr2,624Average Price Targetkr2,080Lowest Price Targetkr1,551
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on SE:AZN
Richard Vosser
J.P. Morgan
J.P. Morgan
kr2,120.5
Buy
36.02%
Upside
Reiterated
10/21/26
AstraZeneca (AZN) Receives a Buy from J.P. Morgan
RBC Capital Analyst forecast on SE:AZN
Trung Huynh
RBC Capital
RBC Capital
kr1,921.48
Buy
23.25%
Upside
Reiterated
10/20/26
AstraZeneca (AZN) Gets a Buy from RBC Capital
Jefferies Analyst forecast on SE:AZN
Michael Leuchten
Jefferies
Jefferies
kr2,319.29
Buy
48.77%
Upside
Reiterated
10/20/26
AstraZeneca (AZN) Receives a Buy from Jefferies
Berenberg Bank Analyst forecast on SE:AZN
Luisa Hector
Berenberg Bank
Berenberg Bank
kr1,987.97
Buy
27.52%
Upside
Reiterated
10/16/26
Berenberg Bank Remains a Buy on AstraZeneca (AZN)
UBS Analyst forecast on SE:AZN
Colin White
UBS
UBS
kr2,014.24
Buy
29.20%
Upside
Reiterated
10/15/26
AstraZeneca (AZN) Receives a Buy from UBS
Deutsche Bank Analyst forecast on SE:AZN
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
kr1,550.61
Hold
-0.54%
Downside
Reiterated
10/14/26
Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)
Nordea Markets Analyst forecast on SE:AZN
Unknown Analyst
Nordea Markets
Not Ranked
Nordea Markets
kr1,650→kr1,900
Buy
21.87%
Upside
Upgraded
10/13/26
AstraZeneca upgraded to Buy from Sell at NordeaAstraZeneca upgraded to Buy from Sell at Nordea
Barclays Analyst forecast on SE:AZN
James Gordon CFA
Barclays
Barclays
kr2,120.5
Buy
36.02%
Upside
Reiterated
10/13/26
Barclays Reaffirms Their Buy Rating on AstraZeneca (AZN)
Citi Analyst forecast on SE:AZN
Graham Parry
Citi
Citi
―
Buy
―
Reiterated
10/12/26
Citi Sticks to Its Buy Rating for AstraZeneca (AZN)
Bernstein Analyst forecast on SE:AZN
Justin Smith
Bernstein
Bernstein
kr2,676.81→kr2,623.81
Buy
68.30%
Upside
Reiterated
10/07/26
Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)
Bank of America Securities Analyst forecast on SE:AZN
Sachin Jain
Bank of America Securities
Bank of America Securities
kr2,186.51
Buy
40.25%
Upside
Reiterated
10/05/26
AstraZeneca: Strong Pipeline and Growth Outlook Support Buy Rating and Unchanged 16,500 GBp Price Target
Goldman Sachs Analyst forecast on SE:AZN
Rajan Sharma
Goldman Sachs
Goldman Sachs
kr2,189.95
Buy
40.47%
Upside
Reiterated
09/29/26
AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN
HSBC Analyst forecast on SE:AZN
Rajesh Kumar
HSBC
HSBC
kr1,822.09→kr1,844.62
Hold
18.32%
Upside
Reiterated
09/10/26
AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBCAstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC
TD Cowen Analyst forecast on SE:AZN
Steve Scala
TD Cowen
TD Cowen
kr2,378.05
Buy
52.54%
Upside
Reiterated
08/31/26
Steve Scala Reiterates Buy on AstraZeneca Citing Above-Peer EPS Growth Outlook and Selective Pipeline Upside
CICC Analyst forecast on SE:AZN
Unknown Analyst
CICC
Not Ranked
CICC
kr1,961.89
Buy
25.84%
Upside
Initiated
08/24/26
AstraZeneca initiated with an Outperform at CICCAstraZeneca initiated with an Outperform at CICC
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on SE:AZN
Richard Vosser
J.P. Morgan
J.P. Morgan
kr2,120.5
Buy
36.02%
Upside
Reiterated
10/21/26
AstraZeneca (AZN) Receives a Buy from J.P. Morgan
RBC Capital Analyst forecast on SE:AZN
Trung Huynh
RBC Capital
RBC Capital
kr1,921.48
Buy
23.25%
Upside
Reiterated
10/20/26
AstraZeneca (AZN) Gets a Buy from RBC Capital
Jefferies Analyst forecast on SE:AZN
Michael Leuchten
Jefferies
Jefferies
kr2,319.29
Buy
48.77%
Upside
Reiterated
10/20/26
AstraZeneca (AZN) Receives a Buy from Jefferies
Berenberg Bank Analyst forecast on SE:AZN
Luisa Hector
Berenberg Bank
Berenberg Bank
kr1,987.97
Buy
27.52%
Upside
Reiterated
10/16/26
Berenberg Bank Remains a Buy on AstraZeneca (AZN)
UBS Analyst forecast on SE:AZN
Colin White
UBS
UBS
kr2,014.24
Buy
29.20%
Upside
Reiterated
10/15/26
AstraZeneca (AZN) Receives a Buy from UBS
Deutsche Bank Analyst forecast on SE:AZN
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
kr1,550.61
Hold
-0.54%
Downside
Reiterated
10/14/26
Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)
Nordea Markets Analyst forecast on SE:AZN
Unknown Analyst
Nordea Markets
Not Ranked
Nordea Markets
kr1,650→kr1,900
Buy
21.87%
Upside
Upgraded
10/13/26
AstraZeneca upgraded to Buy from Sell at NordeaAstraZeneca upgraded to Buy from Sell at Nordea
Barclays Analyst forecast on SE:AZN
James Gordon CFA
Barclays
Barclays
kr2,120.5
Buy
36.02%
Upside
Reiterated
10/13/26
Barclays Reaffirms Their Buy Rating on AstraZeneca (AZN)
Citi Analyst forecast on SE:AZN
Graham Parry
Citi
Citi
―
Buy
―
Reiterated
10/12/26
Citi Sticks to Its Buy Rating for AstraZeneca (AZN)
Bernstein Analyst forecast on SE:AZN
Justin Smith
Bernstein
Bernstein
kr2,676.81→kr2,623.81
Buy
68.30%
Upside
Reiterated
10/07/26
Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)
Bank of America Securities Analyst forecast on SE:AZN
Sachin Jain
Bank of America Securities
Bank of America Securities
kr2,186.51
Buy
40.25%
Upside
Reiterated
10/05/26
AstraZeneca: Strong Pipeline and Growth Outlook Support Buy Rating and Unchanged 16,500 GBp Price Target
Goldman Sachs Analyst forecast on SE:AZN
Rajan Sharma
Goldman Sachs
Goldman Sachs
kr2,189.95
Buy
40.47%
Upside
Reiterated
09/29/26
AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN
HSBC Analyst forecast on SE:AZN
Rajesh Kumar
HSBC
HSBC
kr1,822.09→kr1,844.62
Hold
18.32%
Upside
Reiterated
09/10/26
AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBCAstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC
TD Cowen Analyst forecast on SE:AZN
Steve Scala
TD Cowen
TD Cowen
kr2,378.05
Buy
52.54%
Upside
Reiterated
08/31/26
Steve Scala Reiterates Buy on AstraZeneca Citing Above-Peer EPS Growth Outlook and Selective Pipeline Upside
CICC Analyst forecast on SE:AZN
Unknown Analyst
CICC
Not Ranked
CICC
kr1,961.89
Buy
25.84%
Upside
Initiated
08/24/26
AstraZeneca initiated with an Outperform at CICCAstraZeneca initiated with an Outperform at CICC
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
ONCBeOne Medicines
IRLAIRulya Therapeutics
IDYAIDEAYA Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months
Luisa HectorBerenberg Bank
Success Rate
32/53 ratings generated profit
60%
Average Return
+2.65%
Copying Luisa Hector's trades and holding each position for 3 Months would result in 60.38% of your transactions generating a profit, with an average return of +2.65% per trade.
1 Year
Luisa HectorBerenberg Bank
Success Rate
39/53 ratings generated profit
74%
Average Return
+10.89%
Copying Luisa Hector's trades and holding each position for 1 Year would result in 73.58% of your transactions generating a profit, with an average return of +10.89% per trade.
2 Years
Luisa HectorBerenberg Bank
Success Rate
44/53 ratings generated profit
83%
Average Return
+18.95%
Copying Luisa Hector's trades and holding each position for 2 Years would result in 83.02% of your transactions generating a profit, with an average return of +18.95% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
1
3
5
6
Buy
43
56
61
67
51
Hold
1
1
1
4
4
Sell
8
10
10
8
5
Strong Sell
0
0
0
0
0
total
52
68
75
84
66
In the current month, AZN has received 57 Buy Ratings, 4 Hold Ratings, and 5 Sell Ratings. AZN average Analyst price target in the past 3 months is 2,079.96.
Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is kr25.67 with a range of kr24.55 to kr26.92. The previous quarter’s EPS was kr26.03. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.
Next quarter’s earnings estimate for AZN is kr25.67 with a range of kr24.55 to kr26.92. The previous quarter’s EPS was kr26.03. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is kr158.56B with a range of kr156.13B to kr161.51B. The previous quarter’s sales results were kr151.82B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.
Next quarter’s sales forecast for AZN is kr158.56B with a range of kr156.13B to kr161.51B. The previous quarter’s sales results were kr151.82B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Stock Forecast FAQ

What is SE:AZN’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 2,079.96.
    What is SE:AZN’s upside potential, based on the analysts’ average price target?
    AstraZeneca PLC has 33.42% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AstraZeneca PLC a Buy, Sell or Hold?
          AstraZeneca PLC has a consensus rating of Strong Buy, which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.
            What is AstraZeneca PLC’s share price target?
            The average share price target for AstraZeneca PLC is 2,079.96. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is kr2,623.81 ,and the lowest forecast is kr1,550.61. The average share price target represents 33.42% Increase from the current price of kr1,559.
              What do analysts say about AstraZeneca PLC?
              AstraZeneca PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of AstraZeneca PLC?
                To buy shares of SE:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.